• 1
    Dalal, M. A., Schuld, A., Haack, M., Uhr, M., Geisler, P., Eisensehr, I., Noachtar, S. and Pollmacher, T. Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology, 2001, 56: 17491751.
  • 2
    Diagnostic Classification Steering Committee (Thorpy, M. J., Chairman). International Classification of Sleep Disorders: Diagnostic and Coding Manual. American Sleep Disorders Association, Rochester, MN, USA, 1990.
  • 3
    Honda, Y. Clinical features of narcolepsy: Japanese experience. In: Y. Honda and T. Juji (Eds) HLA in Narcolepsy. Springer-Verlag, Berlin, 1988, pp. 24–57.
  • 4
    Nishino, S., Ripley, B., Overeem, S., Nevsimalova, S., Lammers, G. J., Vankova, J., Okun, M., Rogers, W., Brooks, S. and Mignot, E. Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann. Neurol., 2001, 50: 381388.
  • 5
    Tsukamoto, H., Ishikawa, T., Fujii, Y., Fukumizu, M., Sugai, K. and Kanbayashi, T. Undetectable Level of CSF hypocretin-1 (Orexin-A) in prepubertal boys with narcolepsy. Neuropediatrics (in press).